Vaccination with Autologous Dendritic Cells Loaded with Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.

NCT ID: NCT02919644

Last Updated: 2024-09-19

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 19 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-12-02
• Study Completion Date: 2031-12-31

Brief Summary

Single-arm, monocentric trial to assess safety and immunological efficacy of adjuvant vaccination with autologous dendritic cells loaded with autologous tumour homogenate after curative resection for stage IV colorectal cancer

Detailed Description

Vaccination with autologous dendritic cells loaded with autologous tumour homogenate after curative resection for stage IV colorectal cancer: a phase II study.

Primary objectives: Safety Immunological efficacy, expressed as number of patients who show enhancement of the proportion of circulating immune effectors specific for a selected panel of Colon-Rectal Cancer (CRC)-associated antigens.

Secondary objectives: Clinical outcome of the patients (OS, RFS, TTR). To evaluate the predictive role of the development of a positive DTH test after at least three vaccine administrations.

To evaluate the persistence of an antitumor immune response after the completion of the vaccination program.

To evaluate the prognostic or predictive role of the enhancement of a specific immune response.

To evaluate a panel of inflammatory cytokines involved in antitumor immune response.

To evaluate the predictive role of immune cells in tumour microenvironment. To evaluate the predictive role of tumour antigen expression.

This is a two-stage, phase 2 clinical trial designed according to Simon minimax design. A 40% immune response rate would preclude further studies, while a 70% immune response rate would indicate that further studies would be warranted. Given α and β error of 0.1, the first stage will require enrolment of 7 patients. If at least 3 patients show an immune response and toxicity is acceptable, the study will proceed to the second stage and additional 12 patients will be enrolled.

The vaccine will be considered immunologically active if at least 11 patients are immunological responders.

Conditions

Stage IV Colorectal Cancer; Curative Resection

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

vaccine + Interleukin -2 (IL2)

autologous dendritic cells loaded with autologous tumour homogenate given by intradermal injection (day 1), followed by IL-2 given by subcutaneous injection daily for five days (days 3-7)

Group Type: EXPERIMENTAL

autologous dendritic cells loaded with autologous tumour homogenate

Intervention Type: BIOLOGICAL

Each vaccine dose consists of 10\_7 autologous dendritic cells loaded with autologous tumor homogenate

IL2

Intervention Type: DRUG

Each vaccine dose is followed, after two days, by IL-2 as adjuvant, at a dose of 3 MU daily for five consecutive days

Interventions

autologous dendritic cells loaded with autologous tumour homogenate

Each vaccine dose consists of 10\_7 autologous dendritic cells loaded with autologous tumor homogenate

Intervention Type: BIOLOGICAL

IL2

Each vaccine dose is followed, after two days, by IL-2 as adjuvant, at a dose of 3 MU daily for five consecutive days

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Patients must have histologically confirmed stage IV colorectal cancer surgically treated with radical intent.

2. The autologous surgical specimen must have been collected and sent to the Somatic Cell Therapy Lab of Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST IRCCS) and must fulfil all the acceptance criteria prescribed by the Good Manufacturing practise (GMP) procedures.

3. The patient must be disease-free, as assessed by CT scan or MRI of the chest, abdomen, pelvis performed within 60 days before enrolment. If the resected lesions had occurred in other sites, these must be also included in the baseline CT scan and in all the subsequent evaluations.

4. The patient must have recovered (grade 1 or less by CTCAE 4.0) from all the adverse events related to previous surgery.

5. Age >18 years.

6. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

7. Patient must have acceptable organ function, defined as:

1. Haemoglobin >10 g/dl

2. White blood cells ≥4000/μl.

3. Absolute neutrophil count >1500/μl.

4. Platelets ≥100000/μl.

5. aspartate aminotransferase (AST) and Alanine Aminotransferase (ALT) <3 times the upper institutional reference level.

6. Total bilirubin <1.5 times the upper institutional reference level.

7. Serum creatinine <1.5 times the upper institutional reference level.

8. Patients aged 70 years or older must have left ventricular ejection fraction not lower than 55% as assessed by echocardiography.

9. Female patients of childbearing potential and all male patients must accept and be compliant with an highly effective contraceptive method (i.e. with a failure rate of <1% per year: double barrier method, one barrier method plus spermicidal, intrauterine device, or oral contraception) from informed consent signature and up to three months after end of study. For this purpose are considered of childbearing potential all female subjects after puberty unless they are post-menopausal for at least two years or are surgically sterile. Complete abstinence from sexual intercourses is acceptable if patients' lifestyle guarantees his/her strict compliance with this prescription in the judgement of the Investigator.

10. The patient is willing and able to give written informed consent for the study.

Exclusion Criteria

1. Patients with residual disease after surgery. Marginal resection of any lesion in the absence of clinically evident residual disease is acceptable.

2. Patients who relapsed within 6 months since primary treatment of stage I-III colorectal cancer. If adjuvant chemotherapy had been administered, the term must be computed since last chemotherapy dose.

3. Patient who completed surgery more than 60 days before study enrolment.

4. History of other neoplastic diseases in the previous 5 years, except basal cell carcinoma of the skin and in situ carcinoma of the cervix uteri treated with curative surgery.

5. History of congenital or acquired immunodeficiency, including history of organ transplantation.

6. Any positivity for the serologic markers of hepatitis B virus (HBV) (including at least anti-HBs antibodies and anti-hepatitis B core (HBc) antibodies), hepatitis C virus (HCV), HIV or Treponema pallidum. The serologic tests must have been performed within 30 days before any GMP-regulated activity (i.e. surgical resection and leukapheresis). The sole positivity for antibodies against the HBV S antigen (i.e. with all other HBV markers negative) is indicative of previous HBV vaccination and therefore is acceptable.

7. Female patients who are pregnant or nursing.

8. Patients undergone surgery after preoperatory chemotherapy with a fluoropyrimidine plus oxaliplatin, unless they are not candidate for postoperatory chemotherapy with the same schedule in the opinion of the Investigator (e.g. for unacceptable toxicity) or refuse completion of the perioperatory treatment.

9. Participation in another clinical trial with any investigational agent within 30 days prior to study screening.

10. Any active inflammatory or autoimmune disease requiring systemic steroids or other immunomodulatory agents as detailed in section 6.4, or potentially requiring such treatments during the study treatment in the judgement of the Investigator.

11. Any clinical condition that, in the opinion of the Investigator or the Transfusion Medicine specialist, is a contraindication to leukapheresis. In addition, all patients aged 70 or older must be evaluated by a cardiology specialist before the procedure to exclude any clinically relevant cardiac condition and any grade 3-4 cardiac arrhythmia, even if asymptomatic.

12. Any clinical condition that, in the opinion of the Investigator, contraindicates the subcutaneous administration of low-dose IL-2 as per protocol (see section 6.2 for details).

13. Any uncontrolled serious intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations potentially impacting patient safety and compliance in the opinion of the Investigator.

14. Refusal of giving written informed consent.

• Minimum Eligible Age: 19 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Francesco De Rosa, MD

Role: PRINCIPAL_INVESTIGATOR

UO Immunoterapia e Laboratorio TCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) S.r.l IRCCS

Locations

UO Immunoterapia e Laboratorio TCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) S.r.l IRCCS

Meldola, FC, Italy

Site Status: RECRUITING

CRO-IRCCS Aviano

Aviano, , Italy

Site Status: NOT_YET_RECRUITING

Countries

Italy

Central Contacts

Oriana Nanni, PhD

Role: CONTACT

oriana.nanni@irst.emr.it

+390543739266

Facility Contacts

Francesco De Rosa, MD

Role: primary

francesco.derosa@irst.emr.it

+390543 739274

Angela Buonadonna, MD

Role: primary

Other Identifiers

2015-000894-11

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

IRST153.04

Identifier Type: -

Identifier Source: org_study_id